MS

Manish Sureshbhai Kotecha

Active Director Director DIN 10536393
DIN 10536393 First appointment Mar 2024 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Manish Sureshbhai Kotecha

Data last updated:

Manish Sureshbhai Kotecha is a Director at Gryphon Pharmaceuticals Private Limited (since 2024). The company operates in Paper.

DIN 10536393
Primary Designation Director
Industry Paper
First Appointment 05 Mar 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director05 Mar 20242024Active

Board colleagues of Manish Sureshbhai Kotecha

NameDINCompanyDesignation
Hetal Manishbhai Kotecha10610165Gryphon Pharmaceuticals Private LimitedIndividual Subscriber

Directorship timeline

Open interactive timeline →
Gryphon Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Manish Sureshbhai Kotecha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manish Sureshbhai Kotecha

Manish Sureshbhai Kotecha currently holds 1 directorship: Gryphon Pharmaceuticals Private Limited (Director, since 05 Mar 2024).

Manish Sureshbhai Kotecha was first appointed on 05 Mar 2024 as Director at Gryphon Pharmaceuticals Private Limited.

The current boards of Manish Sureshbhai Kotecha's companies include Hetal Manishbhai Kotecha (Gryphon Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available